Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Robak T, Wierzbowska A . Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009; 31: 2349–2370.

    Article  CAS  PubMed  Google Scholar 

  2. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID . Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986; 67: 1048–1053.

    CAS  PubMed  Google Scholar 

  3. Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G et al. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest 2007; 37: 73–82.

    Article  CAS  PubMed  Google Scholar 

  4. Horton SJ, Huntly BJ . Recent advances in acute myeloid leukemia stem cell biology. Haematologica 2012; 97: 966–974.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Walter RB, Appelbaum FR, Estey EH, Bernstein ID . Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012; 119: 6198–6208.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE(®) antibody construct. Leukemia 2012; e-pub ahead of print 14 December 2012 doi:10.1038/leu.2012.341.

    Article  PubMed  Google Scholar 

  7. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106: 4086–4092.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Stamova S, Cartellieri M, Feldmann A, Arndt C, Koristka S, Bartsch H et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol 2011; 49: 474–482.

    Article  CAS  PubMed  Google Scholar 

  9. Stamova S, Cartellieri M, Feldmann A, Bippes CC, Bartsch H, Wehner R et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 2011; 25: 1053–1056.

    Article  CAS  PubMed  Google Scholar 

  10. Feldmann A, Arndt C, Töpfer K, Stamova S, Krone F, Cartellieri M et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol 2012; 189: 3249–3459.

    Article  CAS  PubMed  Google Scholar 

  11. Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt A, Stamova S et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol 2012; 188: 1551–1558.

    Article  CAS  PubMed  Google Scholar 

  12. Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee D, Yvon E et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33+ acute myeloid leukemia. Adv Hematol 2012; 2012: 683065.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Robertson MJ, Soiffer RJ, Freedmann AA, Rabinowe SL, Anderson KC, Ervin TJ . Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 1992; 79: 2229–2236.

    CAS  PubMed  Google Scholar 

  14. Jing D, Fonseca AV, Alakel N, Fierro FA, Muller K, Bornhauser M et al. Hematopoietic stem cells in co-culture with mesenchymal stromal cells--modeling the niche compartments in vitro. Haematologica 2010; 4: 542–550.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Livia Schulze, Kristin Heidel, Barbara Uteß and Christine Gräfe for excellent technical assistance, Professor Dr Dirk Lindemann for providing us with the lentiviral vector system, and Professor Dr Christian Thiede for providing the CD33+ cell lines MOLM-13, MV4-11 and OCI-AML3. This study was supported by grants of the Medical faculty of the TU Dresden to MC and the Deutsche José Carreras Leukämie-Stiftung e.V. to MB.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Bachmann.

Ethics declarations

Competing interests

MB, SS and GE have filed patent applications related to the Ab directed to CD33. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arndt, C., von Bonin, M., Cartellieri, M. et al. Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 27, 964–967 (2013). https://doi.org/10.1038/leu.2013.18

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.18

This article is cited by

Search

Quick links